Annals of Surgical Oncology

, Volume 19, Issue 2, pp 402–408

Prognostic Value of Putative Circulating Cancer Stem Cells in Patients Undergoing Hepatic Resection for Colorectal Liver Metastasis

  • Pierluigi Pilati
  • Simone Mocellin
  • Loris Bertazza
  • Francesca Galdi
  • Marta Briarava
  • Enzo Mammano
  • Emanuela Tessari
  • Giorgio Zavagno
  • Donato Nitti
Colorectal Cancer

DOI: 10.1245/s10434-011-2132-2

Cite this article as:
Pilati, P., Mocellin, S., Bertazza, L. et al. Ann Surg Oncol (2012) 19: 402. doi:10.1245/s10434-011-2132-2

Abstract

Background

Although surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease. We tested the hypothesis that the detection of circulating tumor cells (CTC) might identify patients at high risk of dying of disease recurrence after apparently radical liver surgery.

Methods

We considered 50 patients undergoing radical surgery for liver-confined hepatic metastasis from CRC. The expression of a panel of cancer-related genes, as assessed by quantitative real-time PCR, was used to detect CTC in the peripheral blood of these patients immediately before surgery. Survival analysis was performed by the Cox regression model.

Results

Univariate analysis of the expression levels of CD133 (a marker of colon cancer stem cells) and survivin (an antiapoptotic factor) resulted in statistically significant association with patient survival [hazard ratio (HR) 2.7, 95% confidence interval (CI) 1.9–3.7, P < 0.0001; and hazard ratio 2.1, 95% CI 1.4–3.2, P < 0.0001, respectively]. Remarkably, multivariate analysis found that only the transcriptional amount of CD133 resulted in statistical significance (HR 2.6, 95% CI 1.9–3.6, P < 0.0001), indicating that this biomarker can independently predict the survival of these patients.

Conclusions

CD133-positive CTC may represent a suitable prognostic marker to stratify the risk of patients who undergo liver resection for CRC metastasis, which opens the avenue to identifying and potentially monitoring the patients who are most likely to benefit from adjuvant treatments.

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Pierluigi Pilati
    • 1
  • Simone Mocellin
    • 1
  • Loris Bertazza
    • 1
    • 2
  • Francesca Galdi
    • 1
  • Marta Briarava
    • 1
  • Enzo Mammano
    • 1
  • Emanuela Tessari
    • 1
  • Giorgio Zavagno
    • 1
  • Donato Nitti
    • 1
  1. 1.Surgery Branch, Department of Oncological and Surgical SciencesUniversity of PadovaPadovaItaly
  2. 2.Istituto Oncologico Veneto (IOV-IRCCS)PadovaItaly